BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34321486)

  • 1. A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays.
    Ni Y; Rosier BJHM; van Aalen EA; Hanckmann ETL; Biewenga L; Pistikou AM; Timmermans B; Vu C; Roos S; Arts R; Li W; de Greef TFA; van Borren MMGJ; van Kuppeveld FJM; Bosch BJ; Merkx M
    Nat Commun; 2021 Jul; 12(1):4586. PubMed ID: 34321486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical performance of the Advia Centaur anti-SARS-CoV-2 chemiluminescent immunoassay related to antibody kinetics.
    Ocmant A; Roisin S; De Meuter R; Brauner J
    J Med Virol; 2021 May; 93(5):2583-2584. PubMed ID: 33448403
    [No Abstract]   [Full Text] [Related]  

  • 3. Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain.
    Poljak M; Oštrbenk Valenčak A; Štamol T; Seme K
    J Clin Virol; 2021 Apr; 137():104784. PubMed ID: 33711693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.
    Grenache DG; Ye C; Bradfute SB
    J Appl Lab Med; 2021 Mar; 6(2):491-495. PubMed ID: 33098417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test.
    Heggestad JT; Kinnamon DS; Olson LB; Liu J; Kelly G; Wall SA; Oshabaheebwa S; Quinn Z; Fontes CM; Joh DY; Hucknall AM; Pieper C; Anderson JG; Naqvi IA; Chen L; Que LG; Oguin T; Nair SK; Sullenger BA; Woods CW; Burke TW; Sempowski GD; Kraft BD; Chilkoti A
    Sci Adv; 2021 Jun; 7(26):. PubMed ID: 34172447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Potential of a Luminex-Based Coronavirus Disease 2019 Suspension Immunoassay (COVID-19 SIA) for the Detection of Antibodies against SARS-CoV-2.
    Hoffman T; Kolstad L; Lindahl JF; Albinsson B; Bergqvist A; Rönnberg B; Lundkvist Å
    Viruses; 2021 May; 13(6):. PubMed ID: 34073484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2.
    Rusanen J; Kareinen L; Levanov L; Mero S; Pakkanen SH; Kantele A; Amanat F; Krammer F; Hedman K; Vapalahti O; Hepojoki J
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectral image contrast-based flow digital nanoplasmon-metry for ultrasensitive antibody detection.
    Wang SH; Kuo CW; Lo SC; Yeung WK; Chang TW; Wei PK
    J Nanobiotechnology; 2022 Jan; 20(1):6. PubMed ID: 34983543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
    Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management.
    Speletas M; Kyritsi MA; Vontas A; Theodoridou A; Chrysanthidis T; Hatzianastasiou S; Petinaki E; Hadjichristodoulou C
    Front Immunol; 2020; 11():609242. PubMed ID: 33424863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.
    Infantino M; Grossi V; Lari B; Bambi R; Perri A; Manneschi M; Terenzi G; Liotti I; Ciotta G; Taddei C; Benucci M; Casprini P; Veneziani F; Fabbri S; Pompetti A; Manfredi M
    J Med Virol; 2020 Sep; 92(9):1671-1675. PubMed ID: 32330291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection.
    Elledge SK; Zhou XX; Byrnes JR; Martinko AJ; Lui I; Pance K; Lim SA; Glasgow JE; Glasgow AA; Turcios K; Iyer NS; Torres L; Peluso MJ; Henrich TJ; Wang TT; Tato CM; Leung KK; Greenhouse B; Wells JA
    Nat Biotechnol; 2021 Aug; 39(8):928-935. PubMed ID: 33767397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2.
    Lapuente D; Maier C; Irrgang P; Hübner J; Peter AS; Hoffmann M; Ensser A; Ziegler K; Winkler TH; Birkholz T; Kremer AE; Steininger P; Korn K; Neipel F; Überla K; Tenbusch M
    Eur J Clin Microbiol Infect Dis; 2021 Apr; 40(4):751-759. PubMed ID: 33078221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay.
    Kittel M; Findeisen P; Muth MC; Thiaucourt M; Gerhards C; Neumaier M; Haselmann V
    Int J Infect Dis; 2021 Apr; 105():632-638. PubMed ID: 33578017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The complexities of SARS-CoV-2 serology.
    Houlihan CF; Beale R
    Lancet Infect Dis; 2020 Dec; 20(12):1350-1351. PubMed ID: 32979317
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19.
    Flinck H; Rauhio A; Luukinen B; Lehtimäki T; Haapala AM; Seiskari T; Aittoniemi J
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115197. PubMed ID: 32977117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests.
    De Marco Verissimo C; O'Brien C; López Corrales J; Dorey A; Cwiklinski K; Lalor R; Doyle JM; Field S; Masterson C; Ribes Martinez E; Hughes G; Bergin C; Walshe K; McNicholas B; Laffey JG; Dalton JP; Kerr C; Doyle S
    Epidemiol Infect; 2021 Jun; 149():e140. PubMed ID: 34099081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.